<DOC>
	<DOC>NCT00330759</DOC>
	<brief_summary>The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (ZometaÂ®) in the treatment of bone metastases (lytic bone lesions from multiple myeloma) in subjects with advanced cancer and multiple myeloma (excluding breast and prostate cancer)</brief_summary>
	<brief_title>Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms, Second Primary</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Adults with histologically/cystologically confirmed advanced cancers including solid tumors, multiple myeloma, and lymphoma Radiographic evidence of at least one bone metastasis (or lytic bone lesion from multiple myeloma); ECOG performance status 0, 1, or 2 Adequate organ function Diagnosis of breast or prostate cancer Current or prior intravenous bisphosphonate administration Current or prior oral bisphosphonates for bone metastases, life expectancy of less than 6 months Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Bone metastases</keyword>
	<keyword>lytic bone lesions</keyword>
	<keyword>advanced cancer</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>lymphoma</keyword>
	<keyword>solid tumors</keyword>
	<keyword>skeletal related events</keyword>
	<keyword>skeletal fractures</keyword>
	<keyword>spinal cord compressions, radiation to bone</keyword>
	<keyword>surgery to bone, bisphosphonates</keyword>
	<keyword>denosumab</keyword>
</DOC>